KM modeling was used to analyze OS in the CET and ET cohorts (2013–2016) stratifying for Anti-Her2 administration, adjusting for patient age, comorbidity score, insurance coverage, tumor stage, ILC histology, and RT use. Here, ERBB2 is linked to neoplasm.